Heike Wulff Selected Research

senicapoc

1/2020	Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.
4/2019	Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
1/2018	KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
1/2013	K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma.
1/2007	Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Heike Wulff Research Topics

Disease

16	Autoimmune Diseases (Autoimmune Disease) 08/2020 - 09/2003
10	Inflammation (Inflammations) 04/2022 - 06/2007
8	Neuroinflammatory Diseases 01/2022 - 12/2016
8	Neoplasms (Cancer) 09/2019 - 01/2013
7	Seizures (Absence Seizure) 01/2022 - 01/2016
7	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 01/2017
6	Ischemic Stroke 12/2021 - 12/2011
6	Multiple Sclerosis 05/2009 - 04/2004
5	Ataxia (Dyssynergia) 01/2022 - 01/2007
5	Stroke (Strokes) 10/2021 - 12/2011
5	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2014 - 06/2007
4	Fibrosis (Cirrhosis) 04/2022 - 08/2009
4	Infarction (Infarctions) 01/2018 - 01/2007
4	Ischemia 01/2018 - 12/2011
4	Asthma (Bronchial Asthma) 10/2013 - 08/2009
3	Cerebellar Ataxia (Dysmetria) 01/2022 - 10/2013
3	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2022 - 08/2015
3	Hyperplasia 01/2020 - 09/2003
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2019 - 12/2011
3	Epilepsy (Aura) 07/2017 - 01/2007
3	Idiopathic Pulmonary Fibrosis 01/2015 - 01/2013
3	Hypertension (High Blood Pressure) 09/2013 - 02/2009
3	Rheumatoid Arthritis 12/2010 - 11/2006
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2007 - 12/2004
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 01/2017
2	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2021 - 01/2012
2	Parkinson Disease (Parkinson's Disease) 12/2021 - 01/2007
2	Cardiac Arrhythmias (Arrythmia) 01/2021 - 01/2021
2	Status Epilepticus (Complex Partial Status Epilepticus) 11/2020 - 01/2020
2	Gliosis 11/2020 - 01/2017
2	Skin Diseases (Skin Disease) 01/2020 - 06/2007
2	Sickle Cell Anemia (Hemoglobin S Disease) 04/2019 - 01/2007
2	Brain Neoplasms (Brain Tumor) 02/2019 - 01/2018
2	Glioma (Gliomas) 01/2018 - 05/2016
2	Hypoxia (Hypoxemia) 01/2018 - 01/2018
2	Brain Edema (Cerebral Edema) 01/2017 - 01/2015
2	Amyloid Plaque 01/2017 - 02/2011
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2015 - 01/2013
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2014 - 01/2010
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2007 - 11/2006
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 04/2022
1	Weight Gain 12/2021
1	Encephalitis (Encephalitis, Rasmussen) 02/2021
1	Poisoning 01/2021
1	Substance-Related Disorders (Drug Abuse) 01/2021

Drug/Important Bio-Agent (IBA)

17	TRAM 34IBA 01/2022 - 09/2003
11	Potassium Channels (Potassium Channel)IBA 01/2021 - 12/2004
8	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 05/2018 - 01/2002
7	Pharmaceutical PreparationsIBA 01/2022 - 06/2007
5	senicapocIBA 01/2020 - 01/2007
5	Ion Channels (Ion Channel)IBA 01/2020 - 01/2002
4	CalciumIBA 01/2022 - 12/2011
4	BenzodiazepinesIBA 01/2022 - 06/2016
4	Kv1.3 Potassium ChannelIBA 12/2021 - 11/2006
4	tetramethylenedisulfotetramine (DSTA)IBA 01/2021 - 01/2020
4	CytokinesIBA 01/2020 - 06/2007
4	Amyloid (Amyloid Fibrils)IBA 04/2019 - 02/2011
4	naphtho(1,2-d)thiazol-2-ylamineIBA 07/2014 - 02/2009
4	CollagenIBA 02/2013 - 09/2003
3	PotassiumIBA 01/2022 - 09/2014
3	ConvulsantsIBA 01/2021 - 01/2020
3	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 01/2019 - 09/2003
3	Immunologic Factors (Immunomodulators)IBA 01/2018 - 06/2004
3	Peptides (Polypeptides)IBA 01/2017 - 04/2005
3	Proteins (Proteins, Gene)FDA Link 01/2015 - 02/2011
2	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 01/2022 - 08/2015
2	Minocycline (Cyclops)FDA LinkGeneric 01/2022 - 01/2018
2	Diazepam (Valium)FDA LinkGeneric 11/2020 - 06/2016
2	Isoflurophate (DFP)FDA Link 11/2020 - 01/2016
2	Midazolam (Versed)FDA LinkGeneric 11/2020 - 06/2016
2	PicrotoxinIBA 01/2020 - 01/2020
2	Glutamic Acid (Glutamate)FDA Link 01/2018 - 02/2015
2	4- ((3- (trifluoromethyl)phenyl)methyl)- 2H- 1,4- benzothiazin- 3(4H)- oneIBA 01/2018 - 01/2013
2	Fatty Acids (Saturated Fatty Acids)IBA 06/2016 - 08/2014
2	Neuroprotective AgentsIBA 01/2016 - 01/2012
2	Angiotensin IIIBA 09/2015 - 02/2009
2	polyglutamineIBA 08/2015 - 09/2011
2	Interleukin-17 (Interleukin 17)IBA 11/2014 - 06/2007
2	Intermediate-Conductance Calcium-Activated Potassium ChannelsIBA 05/2013 - 09/2008
2	ApaminIBA 02/2013 - 01/2007
2	Potassium Channel Blockers (Blockers, Potassium Channel)IBA 09/2008 - 02/2007
1	DystrophinIBA 04/2022
1	Calcibiotic Root Canal SealerIBA 01/2022
1	BarbituratesIBA 01/2022
1	NeurosteroidsIBA 01/2022
1	Propofol (Diprivan)FDA LinkGeneric 01/2022
1	cyclonite (RDX)IBA 01/2022
1	Explosive Agents (Explosives)IBA 01/2022
1	NS 1619IBA 01/2022
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 12/2021
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 12/2021
1	Adenosine Triphosphate (ATP)IBA 02/2021
1	Hallucinogens (Psychedelics)IBA 01/2021
1	GABA Receptors (GABA Receptor)IBA 01/2021
1	Sotalol (Sotalol Hydrochloride)FDA LinkGeneric 01/2021
1	Ibogaine (Endabuse)IBA 01/2021

Therapy/Procedure

18	Therapeutics 10/2021 - 09/2003
3	Immunomodulation 01/2019 - 04/2005
2	Radiotherapy 02/2019 - 05/2016
2	Immunotherapy 12/2014 - 01/2013